Next Investors logo grey
  1. Home
  2. Cbd

Cbd

Neurotech Demonstrates Potential Benefits for Management of Multiple Sclerosis Disease

Finfeed Archived May 25, 2021

Initial in vitro studies carried out by Neurotech International Limited (ASX: NTI) in collaboration with the internationally recognised Neurodevelopment in Health and Disease Laboratory at RMIT University to assess the effects of the lead NTI/Dolce strains on key neuro-markets that are used in assessing the onset and progression of Multiple Sclerosis (MS).

Revenue generating BDA sets its sights on US market

Finfeed Archived Mar 17, 2021

Bod Australia (ASX: BDA) is a cannabis centric healthcare company, with well-branded premium, proven and trusted products within two distinct verticals: Medical Cannabis and CBD and Hemp Consumer products.

Neurotech expands exclusive license to include all neurological disorders

Finfeed Archived Mar 02, 2021

Neurotech International Limited (ASX: NTI) has expanded its exclusive license with Dolce Cann Global Pty Ltd to now include all neurological disorders, disease or affliction affecting the human brain function, specifically - Autism, Epilepsy, ADHD, Alzheimer’s disease, Huntington’s disease, Multiple Sclerosis, Transverse Myelitis, Inflammatory Brain disease, Fibromyalgia, Chronic Fatigue and Migraine.

Neurotech’s key near-term objectives

Finfeed Archived Jan 21, 2021

Neurotech International Limited (ASX: NTI) has provided a comprehensive overview and update regarding the company’s cannabis strains, development strategy and some of the key near-term objectives expected to be delivered.

NTI Days Away from Crucial Lab Results – Can its Cannabis Strain Treat Autism?

Catalyst Hunter Archived Dec 16, 2020

Neurotech International Ltd (ASX: NTI) is focused on the clinical applications of unique cannabis strains to treat neurological disorders such as autism and is set to commence human clinical trials early in 2021.

$2M in repeat purchase orders display Creso Pharma’s growth potential

Finfeed Archived Oct 13, 2020

Creso Pharma Limited (ASX: CPH, FRA: 1X8) has once again strengthened its revenue profile with another repeat purchase order from South African-based Pharma Dynamics.

How (and why) companies are mixing Terpenes into Cannabis Distillates

Finfeed Archived May 29, 2020

Cannabis enthusiasts purchase terps and incorporate them into everything from homemade brownies to vape juice. But there’s one industry that’s had surprisingly less of a symbiotic relationship with terpenes than anyone might have expected; namely the cannabis industry.

Creso’s New Immunity Boosting CBD Hemp Teas Set for Release

Next Investors Archived Mar 24, 2020

Creso Pharma Limited (ASX: CPH) is expanding its available product line with the release of a hemp tea in Q3 2020.

Creso Pharma set to expand human health product line with technological breakthrough

Finfeed Archived Feb 06, 2020

Creso Pharma has achieved a key technological milestone, developing its first water-soluble microgranulated hemp plant granules product as an expansion of its cannaQIX® human health product line.

CPH Set to Expand cannaQIX® Product Line After Major Technological Breakthrough

Next Investors Archived Feb 06, 2020

Hot on the heels of major developments in human and animal health, Creso Pharma (ASX:CPH) has achieved another key milestone: a technological breakthrough that will expand its cannaQIX® human health product line,

Roots Makes 2020 The Year of The Cannabis Deal

Next Investors Archived Feb 05, 2020

In January this year, Roots Sustainable Agricultural Technologies Ltd (ASX:ROO) announced it was placing much greater emphasis on pursuing opportunities in the global cannabis sector.

Roots extends sales relationship with Israeli cannabis company

Finfeed Archived Feb 05, 2020

Israeli-based, Roots Sustainable Agricultural Technologies Ltd (ASX:ROO) today announced it has received a further A$30,000 signed order for its RZTO technology.

BPH investee signs JV with cutting edge cannabis researcher

Finfeed Archived Jan 28, 2020

BPH Energy Limited (ASX:BPH) investee Patagonia Genetics SpA has entered into a joint venture agreement with Israeli based research group Bio-Sciences Pharma Ltd (BSP).

CPH’s cannaQIX® Products Have Now Exceeded the 2.5 million Lozenges Sold Milestone

Next Investors Archived Jan 28, 2020

Creso Pharma (ASX:CPH, FRA:1X8) has announced its second major milestone for the year. Today is has informed the market that its flagship cannaQIX® line surpassed the milestone of 100,000 packs sold. The 100,000 pack milestone corresponds to over 2.5 million cannaQIX® lozenges sold since the product’s launch in April 2018.

Creso Pharma’s flagship cannaQIX® exceeds milestone of 2.5 million lozenges sold

Finfeed Archived Jan 28, 2020

Creso Pharma Limited (ASX:CPH, FRA:1X8) has informed the market that its flagship cannaQIX® line surpassed the milestone of 100,000 packs sold. The company has already delivered positive news flow throughout January resulting in its share price increasing by more than 70% from about 11 cents at the start of the month to a high of 19 cents.

Creso Pharma pursuing animal health – a fast growing segment of the cannabis market

Finfeed Archived Jan 24, 2020

Cannabis stocks had a challenging year in 2019, but signs are emerging that a change of fortunes is in-store

CPH Delivers Over 3 Million Anibidiol Doses to Europe's Dogs

Next Investors Archived Jan 21, 2020

Momentum has been building over the last couple of months as CresoPharma (ASX:CPH) outlined its strategy for generating substantial growth in 2020.

Creso delivers robust year-on-year revenue growth

Finfeed Archived Jan 20, 2020

Shares in Creso Pharma Limited (ASX:CPH, FRA:1X8) soared 20% on Friday after the company released its quarterly report for the three months to 31 December, 2019.
Page 1 of 3 next >

Join Our
Mailing List